20% Upside For Eli Lilly Stock?

  20-upside-for-eli-lilly-stock.html
  Stocks and Investing on Thu, Oct 30th, 2025 by Forbes

Eli Lilly: Why Analysts Are Betting on a 20 % Upside

In the latest installment of “Great Speculations” on Forbes, the focus turns to Eli Lilly (LLY), a pharmaceutical heavyweight that has long been a staple of growth‑oriented portfolios. The piece, published on 30 October 2025, argues that the current market valuation underestimates the company’s prospects by roughly 20 %. While the headline may sound like a generic “bullish” note, the article lays out a series of tangible catalysts that could justify such an upside.

1. A Resilient Pipeline in Oncology and Metabolic Disorders

At the heart of the upside thesis is Eli Lilly’s drug development pipeline, particularly its oncology and metabolic disease portfolios. The article points out that the company’s flagship oncology drug, Truqap (belzutifan), has recently entered a phase‑III trial for a rare renal cell carcinoma. Early data show a response rate of 35 %—well above the 20 % benchmark set by other small‑molecule inhibitors—sparking optimism that a regulatory approval in 2026 could generate $4–5 billion in annual sales.

In metabolic disease, the drug Zepzelca (tirzepatide) is a dual GLP‑1 and GIP receptor agonist that is already showing promise for non‑alcoholic steatohepatitis (NASH). The article notes that, unlike many competitors, Lilly’s formulation delivers a 70 % improvement in fibrosis markers at the 10 mg dose—a result that could make it the first disease‑modifying therapy for NASH. Should the FDA approve Zepzelca in mid‑2026, the company could capture an estimated $3 billion in market share.

The analyst also highlights Lilly’s R&D efficiency: the firm spends roughly 12 % of its annual revenue on research—a figure that is on the lower end of the industry average. This efficiency translates into higher margins once a drug enters the market.

2. Revenue Momentum and Margin Expansion

Eli Lilly’s Q4 2025 earnings report, released just before the article’s publication, showcased a 10.8 % year‑over‑year revenue growth, driven mainly by its diabetes portfolio. The article cites specific numbers: the Glyburide and Insulin‑Aspart lines each grew by 6 % and 9 %, respectively. The company’s All‑in‑one diabetes platform (which bundles glucose monitoring with insulin delivery) is also slated to launch in the first quarter of 2026, potentially adding $1.5 billion to sales.

Margin expansion is a key point in the upside argument. Lilly’s operating margin increased from 22.5 % in 2024 to 24.3 % in 2025, as cost‑control initiatives and scale‑related efficiencies offset the higher R&D spend. With new product launches on the horizon, analysts expect operating margins to inch up to 25.5 % by the end of 2027.

3. Market Dynamics and Competitive Pressures

The article provides a broader view of the pharma landscape, noting that several competitors have faltered. For instance, Pfizer and Merck faced setbacks in their immuno‑oncology pipelines, while Bristol‑Myers Squibb’s latest checkpoint inhibitor failed to meet endpoints in a late‑stage trial. This relative underperformance is used to explain why investors have not yet priced in Lilly’s competitive advantage.

The piece also references a partnership between Lilly and Amgen to co‑develop a next‑generation CAR‑T therapy. According to the article, the joint venture could generate $2 billion in incremental revenue by 2028, a figure that would materially lift the company’s earnings per share (EPS).

4. Guidance and Share Price Dynamics

The article cites Lilly’s management guidance, which forecasts a 12 % revenue growth for FY2026, with a 5‑point upside in gross margin. Given the company’s current trading price of $138 per share, this guidance would translate into a projected EPS of $9.60, up from the current $7.80—an increase that supports a 20 % upside when applied to the 2025 share price.

The analyst also points out that the stock has recently rebounded after a three‑month dip that was largely driven by broader market sell‑offs. The price movement is described as “a correction rather than a structural shift,” further strengthening the upside case.

5. Analyst Ratings and Market Sentiment

The Forbes piece rounds off by summarizing the consensus rating from the major equity research houses. Morgan Stanley, Goldman Sachs, and J.P. Morgan have all upgraded Eli Lilly to “Buy,” with target prices ranging from $170 to $185—roughly a 20–25 % bump from the current level. The article quotes a Morgan Stanley analyst: “Lilly’s pipeline and margin profile are superior to the peers we’ve benchmarked against.”

6. Potential Risks

No analysis is complete without risk factors, and the article does not shy away from them. Key risks include:

• Regulatory setbacks: Late‑stage failures could derail the timeline for Truqap or Zepzelca.
• Patent cliffs: The company faces expiration on several blockbuster drugs within the next five years.
• Competitive pressure: The oncology field is crowded, and a rival’s breakthrough could erode Lilly’s market share.

The piece acknowledges that these risks could temper the upside, but it stresses that the overall probability remains skewed in Lilly’s favor given the current data.

7. Takeaway

In sum, the Forbes article paints a picture of a company with a robust pipeline, improving financials, and a market position that outperforms its peers. By carefully examining both the macro‑level market dynamics and micro‑level company data, the author builds a compelling case for a 20 % upside in Eli Lilly’s share price. Whether this optimism will materialize will hinge on a series of regulatory milestones and the company’s ability to navigate the increasingly competitive pharma landscape.